Mersana Therapeutics Investor Relations Material

Mersana Therapeutics Inc., is a biopharmaceutical company focused on discovering and developing a pipeline of antibodies with differentiated and complementary means of targeting cancer. The Company’s lead product candidate is XMT-1522, an ADC that targets the CD38 antigen present on multiple hematological cancers. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics Inc. in November 2005. Mersana Therapeutics Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.